$1.50+0.05 (+3.45%)
BioRestorative Therapies Inc. (BRTX) is a Managed Health Care company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for BRTX, including 1 analyst rating and 1 SEC filing. The most recent was published Oct 9, 2026.
Price$1.50+0.05 (+3.45%)
03:45 PM04:15 PM
News · 26 weeks24-100%
2026-05-102026-11-01
Mix990d
- SEC Filings6(67%)
- Other2(22%)
- Analyst1(11%)
Latest news
25 items- SECSEC Form 8-K filed by BioRestorative Therapies Inc.8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- ANALYSTBioRestorative Therapies downgraded by Maxim GroupMaxim Group downgraded BioRestorative Therapies from Buy to Hold
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECAmendment: BioRestorative Therapies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits8-K/A - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Reverse Stock SplitMELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the "Reverse Stock Split") of the Company’s common stock (the "Common Stock"). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECSEC Form NT 10-Q filed by BioRestorative Therapies Inc.NT 10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- INSIDERSEC Form 3 filed by new insider Randhawa Esha3 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
- INSIDERSEC Form 3 filed by new insider Brown Steven Collier3 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics PlatformMELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company’s vertically integrated regenerative medicine platform. Manufacturing of the BRTX-100 clinical supply was completed in the Company’s cGMP ISO-7 certified facility, supporting ongoing clinical development for the treatment of chron
- INSIDERSEC Form 3 filed by new insider Grasso Mika3 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dhaliwal Jatinder3 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
- PRBioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic GrowthAccomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company's commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market. In this role, Mr. Smith will lead revenue growth initiatives across professional aesthetics, r
- INSIDERSEC Form 3 filed by new insider Field Katharyn3 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- SECBioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRKaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholdersMIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company"). This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.Unfortunately, BRTX shareholders are not currently gaining meaningful valu
- PRBioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataFully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment MELVILLE, N.Y., May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the last patient has been dosed in its fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease (cLDD), completing treatment administration in the Company's lead clinical
- SECSEC Form 10-Q filed by BioRestorative Therapies Inc.10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
- PRBioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsData demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland. The data highlight the functional and proteomic differences of extracellular vesicles ("EVs"), including exosomes, derive
- PRBioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseOral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety signals observed MELVILLE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, the Company's autologous hypoxic-cultured mesenchymal stem cell therapy for the treatment of chronic lumbar disc
BRTX FAQ
7 questionsWhat does BioRestorative Therapies Inc. do?
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical...What is the latest news on BRTX?
In the last 30 days Quantisnow tracked 2 wire items for BRTX: 1 analyst rating and 1 SEC filing. The most recent was published on October 9, 2026.Where does BRTX stock trade?
BioRestorative Therapies Inc. (BRTX) is listed on NASDAQ.What sector and industry is BRTX in?
BioRestorative Therapies Inc. operates in the Health Care sector, Managed Health Care industry.What are analysts saying about BRTX?
Across the last 2 analyst actions on BioRestorative Therapies Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Maxim Group: Hold on 2026-10-06. Recent price targets cluster around $37.00.What companies are similar to BRTX?
Notable peers in the same industry include CLBS (Caladrius Biosciences Inc.), CERN (Cerner Corporation), CHNG (Change Healthcare Inc.), MTBC (CareCloud Inc.), CSLT (Castlight Health Inc.). Compare BRTX side-by-side with any of them on Quantisnow.How can I track BRTX on Quantisnow?
Quantisnow aggregates BioRestorative Therapies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRTX to receive live email and push alerts on every new disclosure.